| __timestamp | Grifols, S.A. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1656170000 | 22732000 |
| Thursday, January 1, 2015 | 2003565000 | 29245000 |
| Friday, January 1, 2016 | 2137539000 | 33206000 |
| Sunday, January 1, 2017 | 2166062000 | 31152000 |
| Monday, January 1, 2018 | 2437164000 | 10136000 |
| Tuesday, January 1, 2019 | 2757459000 | 45546000 |
| Wednesday, January 1, 2020 | 3084873000 | 43367000 |
| Friday, January 1, 2021 | 2970522000 | 81413000 |
| Saturday, January 1, 2022 | 3832437000 | 139304000 |
| Sunday, January 1, 2023 | 4269276000 | 192361000 |
| Monday, January 1, 2024 | 159417000 |
Data in motion
In the ever-evolving pharmaceutical landscape, cost efficiency is a critical metric for success. This analysis delves into the cost of revenue trends for Halozyme Therapeutics, Inc. and Grifols, S.A. from 2014 to 2023. Over this period, Grifols, S.A. consistently demonstrated a robust cost structure, with its cost of revenue peaking at approximately 4.3 billion in 2023, marking a 158% increase from 2014. In contrast, Halozyme Therapeutics, Inc. showcased a more modest growth, with its cost of revenue rising to nearly 192 million in 2023, a significant leap from 2014's 23 million. This disparity highlights Grifols' expansive operational scale compared to Halozyme's more focused approach. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into strategic positioning and market competitiveness.
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: GSK plc and Grifols, S.A.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Catalent, Inc. vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.